Myocardial Ischemia/Reperfusion injury: Potential of TRPV1 agonists as cardioprotective agents

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 14, Issue 1, 2014, Pages 71-78

  Vemula, Praveen ^a   Gautam, Bikki ^a   Abela, George S ^a   Wang, Donna H ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Agonist; Cardioprotection; Ischemia Reperfusion; Myocardium; TRPV1

Indexed keywords

CAPSAICIN; EVODIAMINE; MACROPHAGE INFLAMMATORY PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; NGX 1998; REACTIVE OXYGEN METABOLITE; SA 13353; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1 ANTAGONIST; WL 1001; CARDIOTONIC AGENT; VANILLOID RECEPTOR; VANILLOID RECEPTOR SUBTYPE 1;

APOPTOSIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; INFLAMMATION; MITOCHONDRIAL PERMEABILITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REPERFUSION INJURY; REVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; HEART MUSCLE; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

ANIMALS; CARDIOTONIC AGENTS; HUMANS; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; TRPV CATION CHANNELS;

EID: 84905658053     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871529x13666131129103759     Document Type: Review

References (87)

1. Roger, V.L.; Go, A.S.; Lloyd-Jones, D.M.; Benjamin, E.J.; Berry, J.D.; Borden, W.B.; Bravata, D.M.; Dai, S.; Ford, E.S.; Fox, C.S.; Fullerton, H.J.; Gillespie, C.; Hailpern, S.M.; Heit, J.A.; Howard, V.J.; Kissela, B.M.; Kittner, S.J.; Lackland, D.T.; Lichtman, J.H.; Lisabeth, L.D.; Makuc, D.M.; Marcus, G.M.; Marelli, A.; Matchar, D.B.; Moy, C.S.; Mozaffarian, D.; Mussolino, M.E.; Nichol, G.; Paynter, N.P.; Soliman, E.Z.; Sorlie, P.D.; Sotoodehnia, N.; Turan, T.N.; Virani, S.S.; Wong, N.D.; Woo, D.; Turner, M.B. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation, 2012, 125(1), e2-220.
2. Geltman, E.M; Infarct size as a determinant of acute and long-term prognosis. Cardiol. Clin., 1984, 2, 95-103.
3. Maroko, P.R.; Libby, P.; Ginks, W.R.; Bloor, C.M.; Shell, W.E.; Sobel, B.E.; Ross, J Jr. Coronary artery reperfusion: Early effects on local myocardial function and the extent of myocardial necrosis. J. Clin. Invest., 1972, 51, 2710-2716.
4. Ellis, S.G.; Henschke, C.I.; Sandor, T.; Wynne, J.; Braunwald, E.; Kloner, R.A; Time course of functional and biochemical recovery of myocardium salvaged by reperfusion. J. Am. Coll. Cardiol., 1983, 1, 1047-1055.
5. Braunwald, E.; Kloner, R.A. Myocardial reperfusion: A double-edged sword? J. Clin. Invest., 1985, 76, 1713-1719.
6. Birnbaum, Y.; Leor, J.; Kloner, R.A; Pathobiology and clinical impact of reperfusion injury. J. Thromb. Thrombolysis, 1995, 2, 177-86.
7. Farb, A.; Kolodgie, F.D.; Jenkins, M.; Virmani, R. Myocardial infarct extension during reperfusion after coronary artery occlusion: pathologic evidence. J. Am. Coll. Cardiol., 1993, 21, 1245-53.
8. Kloner, R.A. Does reperfusion injury exist in humans? J. Am. Coll. Cardiol., 1993, 21, 537-45.
9. Minamino, T. Cardioprotection from Ischemia/Reperfusion Injury: Basic and translational research. Circ. J., 2012, 76(5), 1074-82.
10. Hausenloy, D.J.; Duchen, M.R.; Yellon, D.M. Inhibiting mitochondrial permeability transition pore opening at reperfusion protects against ischaemia-reperfusion injury. Cardiovasc. Res., 2003, 60(3), 617-25.
11. Halestrap, A.P.; Clarke, S.J.; Javadov, S.A. Mitochondrial permeability transition pore opening during myocardial reperfusion-a target for cardioprotection. Cardiovasc. Res., 2004, 61(3), 372-85.
12. Halestrap, A.P. Mitochondria and reperfusion injury of the heart-a holey death but not beyond salvation. J. Bioenerg. Biomembr., 2009, 41(2), 113-21.
13. Ryu, S.Y.; Peixoto, P.M.; Teijido, O.; Dejean, L.M.; Kinnally, K.W. Role of mitochondrial ion channels in cell death. Biofactors, 2010, 36(4), 255-63.
14. Ladilov, Y.V.; Siegmund, B.; Balser, C.; Piper, H.M. Simulated ischemia increases the susceptibility of rat cardiomyocytes to hypercontracture. Circ. Res., 1997, 80(1), 69-75.
15. Meissner, A.; Morgan, J.P. Contractile dysfunction and abnormal Ca2 modulation during postischemic reperfusion in rat heart. Am. J. Physiol., 1995, 268(1 Pt 2), H100-11.
16. Imahashi, K.; Pott, C.; Goldhaber, J.I.; Steenbergen, C.; Philipson, K.D.; Murphy, E. Cardiac ablation of the Na+-Ca2+ exchanger confers protection against ischemia/reperfusion injury. Circ. Res., 2005, 97(9), 916-21.
17. Motegi, K.; Tanonaka, K.; Takenaga, Y.; Takagi, N.; Takeo, S. Preservation of mitochondrial function may contribute tocardioprotective effects of Na+/Ca2+ exchanger inhibitors in ischemic/reperfused rat hearts. Br. J. Pharmacol., 2007, 151(7), 963-78.
18. Wei, G.Z.; Zhou, J.J.; Wang, B.; Wu, F.; Bi, H.; Wang, Y.M.; Yi, D.H.; Yu, S.Q.; Pei, J.M. Diastolic Ca2+ overload caused by Na+/Ca2+ exchanger during the first minutes of reperfusion results in continued myocardial stunning. Eur. J. Pharmacol., 2007, 572(1), 1-11.
19. Kaljusto, M.L.; Rutkovsky, A.; Stensløkken, K.O.; Vaage, J. Postconditioning in mouse hearts is inhibited by blocking the reverse mode of the sodium-calcium exchanger. Interact. Cardiovasc. Thorac. Surg., 2010, 10(5), 743-8.
20. Kloner, R.A.; Introduction to the role of oxygen radicals in myocardial ischemia and infarction. Free. Radic. Biol. Med., 1988, 4(1), 5-7.
21. Richard, V.J.; Murry, C.E.; Jennings, R.B.; Reimer, K.A. Oxygen-derived free radicals and postischemic myocardial reperfusion: therapeutic implications. Fundam. Clin. Pharmacol., 1990, 4(1), 85-103.
22. Toyokuni, S.; Reactive oxygen species-induced molecular damage and its application in pathology. Pathol. Int., 1999, 49(2), 91-102.
23. Verma, S.; Fedak, P.W.; Weisel, R.D.; Butany, J.; Rao, V.; Maitland, A.; Li, R.K.; Dhillon, B.; Yau, T.M.; Fundamentals of reperfusion injury for the clinical cardiologist. Circulation, 2002, 105(20), 2332-6.
24. Mehta, J.I.; Nichols, W.W.; Mehta, P.; Neutrophils as potential participants in acute myocardial ischemia: relevance to reperfusion. J. Am. Coll. Cardiol., 1988, 11(6), 1309-16.
25. Jordan, J.E.; Zhao, Z.Q.; Vinten-Johansen, J.; The role of neutrophils in myocardial ischemia-reperfusion injury. Cardiovasc. Res., 1999, 43(4), 860-78.
26. Frangogiannis, N.G.; Smith, C.W.; Entman, M.L. The inflammatory response in myocardial infarction. Cardiovasc. Res., 2002, 53(1), 31-47.
27. Whelan, R.S.; Kaplinskiy, V.; Kitsis, R.N. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu. Rev. Physiol., 2010, 72, 19-44.
28. Murry, C.E.; Jennings, R.B; Reimer, K.A. Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation, 1986, 74, 1124-1136.
29. Yellon, D.M.; Downey, J.M. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol. Rev., 2003, 83(4), 1113-51.
30. Downey, J.M.; Davis, A.M.; Cohen, M.V. Signaling pathways in ischemic preconditioning. Heart Fail. Rev., 2007, 12(3-4), 181-8.
31. Yang, X.; Cohen, M.V.; Downey, J.M. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc. Drugs Ther., 2010, 24(3), 225-34.
32. Peart, J.N.; Headrick, J.P.; Clinical cardioprotection and the value of conditioning responses. Am. J. Physiol. Heart Circ. Physiol., 2009, 296, H1705-H1720.
33. Miura, T.; Tanno, M. The mPTP and its regulatory proteins: Final common targets of signalling pathways for protection against necrosis. Cardiovasc. Res., 2011, 88, 7-15.
34. Zhao, Z.Q.; Corvera, J.S.; Halkos, M.E.; Kerendi, F.; Wang, N.P.; Guyton, R.A.; Vinten-Johansen, J. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: Comparison with ischemic preconditioning. Am. J. Physiol. Heart Circ. Physiol., 2003, 285, H579-H588.
35. Laskey, W.K. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: a pilot study. Catheter. Cardiovasc. Interv., 2005, 65(3), 361-7.
36. Staat, P.; Rioufol, G.; Piot, C.; Cottin, Y.; Cung, T.T.; L'Huillier, I.; Aupetit, J.F.; Bonnefoy, E.; Finet, G.; André-Fouët, X.; Ovize, M. Postconditioning the human heart. Circulation, 2005, 112(14), 2143-8.
37. Ma, X.; Zhang, X.; Li, C.; Luo, M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J. Interv. Cardiol., 2006, 19(5), 367-75.
38. Thibault, H.; Piot, C.; Staat, P.; Bontemps, L.; Sportouch, C.; Rioufol, G.; Cung, T.T.; Bonnefoy, E.; Angoulvant, D.; Aupetit, J.F.; Finet, G.; André-Fouët, X.; Macia, J.C.; Raczka, F.; Rossi, R.; Itti, R.; Kirkorian, G.; Derumeaux, G.; Ovize, M. Long-term benefit of postconditioning. Circulation, 2008, 117(8), 1037-44.
39. Laskey, W.K.; Yoon, S.; Calzada, N.; Ricciardi, M.J. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter. Cardiovasc. Interv., 2008,72(2), 212-20.
40. Li, C.M.; Zhang, X.H.; Ma, X.J.; Luo, M. Limb ischemic postconditioning protects myocardium from ischemia-reperfusion injury. Scand. Cardiovasc. J., 2006, 40(5), 312-7.
41. Hausenloy, D.J.; Mwamure, P.K.; Venugopal, V.; Harris, J.; Barnard, M.; Grundy, E.; Ashley, E.; Vichare, S.; Di Salvo, C.; Kolvekar, S.; Hayward, M.; Keogh, B.; MacAllister, R.J.; Yellon, D.M. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet, 2007, 370(9587), 575-9.
42. Venugopal, V.; Hausenloy, D.J.; Ludman, A.; Di Salvo, C.; Kolvekar, S.; Yap, J.; Lawrence, D.; Bognolo, J.; Yellon, D.M. Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: a randomised controlled trial. Heart, 2009, 95(19),1567-71.
43. Bøtker, H.E.; Kharbanda, R.; Schmidt, M.R. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet, 2010, 375(9716), 727-34.
44. Hausenloy, D.J.; Yellon, D.M. Reperfusion injury salvage kinase signalling: Taking a RISK for cardioprotection. Heart. Fail. Rev., 2007, 12, 217-234.
45. Hausenloy, D.J.; Yellon, D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc. Res., 2004, 61(3), 448-60.
46. Sivaraman, V.; Mudalagiri, N.R.; Di Salvo, C.; Kolvekar, S.; Hayward, M.; Yap, J.; Keogh, B.; Hausenloy, D.J.; Yellon, D.M. Postconditioning protects human atrial muscle through activation of the RISK pathway. Basic Res. Cardiol., 2007, 102(5), 453-9.
47. Hausenloy, D.J.; Tsang, A.; Yellon, D.M. The reperfusion injury salvage kinase pathway: a common target for both ischemic preconditioning and postconditioning. Trends. Cardiovasc. Med., 2005, 15(2), 69-75.
48. Lacerda, L.; Somers, S.; Opie, L.H.; Lecour, S. Ischaemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc. Res., 2009, 84, 201-208.
49. Lecour, S.; Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? J. Mol. Cell. Cardiol., 2009, 47(1), 32-40.
50. Davidson, S.M.; Hausenloy, D.; Duchen, M.R.; Yellon, D.M. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int. J. Biochem. Cell Biol., 2006, 38(3), 414-9.
51. Halestrap, A.P. A pore way to die: the role of mitochondria in reperfusion injury and cardioprotection. Biochem. Soc. Trans., 2010, 38(4), 841-60.
52. Sharma, V.; Bell, R.M.; Yellon, D.M. Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmacotherapy. Expert. Opin. Pharmacother., 2012, 13(8), 1153-75.
53. Gunthorpe, M.J.; Benham, C.D.; Randall, A.; Davis, J.B.The diversity in the vanilloid (TRPV) receptor family of ion channels. Trends Pharmacol. Sci., 2002, 23(4), 183-91.
54. Szallasi, A.; Blumberg, P.M.; Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol. Rev., 1999, 51(2), 159-212.
55. Gou, A.; Vulchanova, L.; Wang, J.; Li, X.; Elde, R. Immunocytochemical localization of the vanilloid receptor 1(VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur. J. Neurosci., 1999, 11(3), 946-58.
56. Acs, G.; Palkovits, M.; Blumberg, P.M. Specific binding of [3H] resiniferatoxin by human and rat preoptic area, locus ceruleus, medial hypothalamus, reticular formation and ventral thalamus membrane preparations. Life. Sci., 1996, 59(22), 1899-908.
57. Zahner, M.R.; Li, D.P.; Chen, S.R.; Pan, H.L.; Cardiac vanilloid receptor 1-expressing afferent nerves and their role in the cardiogenic sympathetic reflex in rats. J. Physiol., 2003, 551(Pt 2), 515-23.
58. Caterina, M.J.; Schumacher, M.A.; Tominaga, M.; Rosen, T.A.; Levine, J.D.; Julius, D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature, 1997, 389(6653), 816-24.
59. Davis, J.B.; Gray, J.; Gunthorpe, M.J.; Hatcher, J.P.; Davey, P.T.; Overend, P.; Harries, M.H.; Latcham, J.; Clapham, C.; Atkinson, K.; Hughes, S.A.; Rance, K.; Grau, E.; Harper, A.J.; Pugh, P.L.; Rogers, D.C.; Bingham, S.; Randall, A.; Sheardown, S.A. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature, 2000, 405(6783), 183-7.
60. Hwang, S.W.; Cho, H.; Kwak, J. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci., 2000, 97(11), 6155-60.
61. Van Der Stelt, M.; Di Marzo, V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur. J. Biochem., 2004, 271(10), 1827-34.
62. Keeble, J.; Russell, F.; Curtis, B.; Starr, A.; Pinter, E.; Brain, S.D. Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum., 2005, 52(10), 3248-56.
63. Demirbilek, S.; Ersoy, M.O.; Demirbilek, S.; Karaman, A.; Gürbüz, N.; Bayraktar, N.; Bayraktar, M. Small-dose capsaicin reduces systemic inflammatory responses in septic rats. Anesth. Analg., 2004, 99(5), 1501-7.
64. Huang, W.; Rubinstein, J.; Preito, A.R.; Thang, L.V.; Wang, D.H. Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction. Hypertension, 2009, 53(2), 243-50.
65. Rayamajhi, S.; Contractor, T.; Wang, D.H. Potential of TRPV1 agonists for treating ischemia/reperfusion-induced renal injuries. Current Opinion in Investigational Drugs, 2009,10(9), 963-970.
66. Cui, M.; Honore, P.; Zhong, C.; Gauvin, D.; Mikusa, J.; Hernandez, G.; Chandran, P.; Gomtsyan, A.; Brown, B.; Bayburt, E.K.; Marsh, K.; Bianchi, B.; McDonald, H.; Niforatos, W.; Neelands, T.R.; Moreland, R.B.; Decker, M.W.; Lee, C.H.; Sullivan, J.P.; Faltynek, C.R. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J. Neurosci., 2006, 26(37), 9385-93.
67. Holzer, P. Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience, 1988, 24(3), 739-68.
68. Hua, F.; Ricketts, B.A.; Reifsteck, A.; Ardell, J.L.; Williams, C.A. Myocardial ischemia induces the release of substance P from cardiac afferent neurons in rat thoracic spinal cord. Am. J. Physiol. Heart Circ. Physiol., 2004, 286(5), H1654-64.
69. Wang, L.; Wang, D.H. TRPV1 gene knockout impairs postischemic recovery in isolated perfused heart in mice. Circulation, 2005, 112(23), 3617-23.
70. Zhong, B.; Wang, D.H. TRPV1 gene knockout impairs preconditioning protection against myocardial injury in isolated perfused hearts in mice. Am. J. Physiol. Heart Circ. Physiol., 2007, 293(3), H1791-8.
71. Huang, W.; Rubinstein, J.; Prieto, A.R.; Thang, L.V.; Wang, D.H. Transient receptor potential vanilloid gene deletion exacerbates inflammation and atypical cardiac remodeling after myocardial infarction. Hypertension, 2009, 53, 243-250.
72. Wei, Z.; Wang, L.; Han, J.; Song, J.; Yao, L.; Shao, L.; Sun, Z.; Zheng, L. Decreased expression of transient receptor potential vanilloid 1 impairs the postischemic recovery of diabetic mouse hearts. Circ. J., 2009, 73(6), 1127-32.
73. Ren, J.Y.; Song, J.X.; Lu, M.Y.; Chen, H.; Cardioprotection by ischemic postconditioning is lost in isolated perfused heart from diabetic rats: Involvement of transient receptor potential vanilloid 1, calcitonin gene-related peptide and substance P. Regul. Pept., 2011, 169(1-3), 49-57.
74. Zhong, B.; Wang, D.H. Protease-activated receptor 2-mediated protection of myocardial ischemia-reperfusion injury: role of transient receptor potential vanilloid receptors. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2009, 297(6), R1681-90.
75. Rang, W.Q.; Du, Y.H.; Hu, C.P.; Ye, F.; Xu, K.P.; Peng, J.; Deng, H.W.; Li, Y.J. Protective effects of evodiamine on myocardial ischemia-reperfusion injury in rats. Planta. Med., 2004, 70(12), 1140-3.
76. Huang, R.; Karve, A.; Shah, I.; Bowers, M.C.; DiPette, D.J.; Supowit, S.C.; Abela, G.S. Deletion of the mouse alpha-calcitonin gene-related peptide gene increases the vulnerability of the heart to ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol., 2008, 294, H1291-7.
77. Sexton, A.; McDonald, M.; Cayla, C.; Thiemermann, C.; Ahluwalia, A. 12-Lipoxygenase-derived eicosanoids protect against myocardial ischemia/reperfusion injury via activation of neuronal TRPV1. FASEB J, 2007, 11, 2695-703.
78. Qin, S.L.; Liu, S.L.; Wang, R.R. Protective effect of capsaicin on against myocardial ischemia-reperfusion injury of rat in vivo. Sichuan Da Xue Xue Bao Yi Xue Ban, 2008, 39(4), 550-4.
79. Zhong, B.; Wang, D.H. N-oleoyldopamine, a novel endogenous capsaicin-like lipid, protects the heart against ischemia-reperfusion injury via activation of TRPV1. Am. J. Physiol. Heart Circ. Physiol., 2008, 295(2), H728-35.
80. [] U.S. Food and Drug Administration. http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/2009/ucm191003.htm [Accessed on: 2 August 2013]
81. Winston Laboratories, Inc. Submits NDA for CIVANEX® (Civamide Cream) for Treatment of Osteoarthritis. Press Release. http://www.winstonlabs.com/files/documents/89_winstonpharmace uticalsjuly7pressreleasenda.pdf [Accessed on: 3 August 2013]
82. Remadevi, R.; Szallisi, A. Adlea (ALGRX-4975), an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. I. Drugs, 2008, 11(2), 120-32.
83. [] Fumio, Tsuji.; Masaaki, Murai.; Kenji, Oki.; Minoru, Sasano.; Hiroyuki, Aono.; Transient Receptor Potential Vanilloid 1 Agonists as Candidates for Anti-inflammatory Agents. Inflammation and Regeneration http://www.jsir.gr.jp/journal/Vol31No1/pdf/12_M2_95.pdf
84. Balmayor, E.R.; Azevedo, H.S.; Reis, R.L. Controlled delivery systems: from pharmaceuticals to cells and genes. Pharm. Res., 2011, 28(6), 1241-58.
85. [] Takahama, H.; Minamino, T.; Asanuma, H.; Fujita, M.; Asai, T.; Wakeno, M.; Sasaki, H.; Kikuchi, H.; Hashimoto, K.; Oku, N.; Asakura, M.; Kim, J.; Takashima, S.; Komamura, K.; Sugimachi, M.; Mochizuki, N.; Kitakaze, M.; Prolonged targeting of ischemic/reperfused myocardium by liposomal adenosine augments cardioprotection in rats. J. Am. Coll. Cardiol., 2009, 53(8), 709-17.
86. Cohen, M.V.; Downey, J.M. Adenosine at reperfusion: A conundrum ready to be resolved. J. Am. Coll. Cardiol., 2009, 53, 718-719.
87. Robbins, N.; Koch, S.E.; Rubinstein, J. Targeting TRPV1 and TRPV2 for potential therapeutic interventions in cardiovascular disease. Transl. Res., 2013, 161(6), 469-76.